Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) today announced the launch of a generic version of Lialda (mesalamine) delayed-release 1.2 gram tablets in the US.
Mesalamine delayed-release tablets are indicated for the induction of remission in adults with active, mild to moderate ulcerative colitis and for the maintenance of remission of ulcerative colitis.
TEVA EVP and head of North America Commercial Brendan O'Grady said, “The launch of mesalamine is a significant addition to Teva’s generic portfolio. With more than a million people in the US estimated to suffer from inflammatory bowel diseases, including ulcerative colitis, this is an important and more affordable generic treatment option for our customers.”
Mesalamine further enhances Teva’s already-comprehensive anti-inflammatory portfolio. With nearly 600 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the US. Currently, one in seven generic prescriptions dispensed in the US is filled with a Teva generic product.
Mesalamine Delayed-Release 1.2 gram tablets had annual sales of approximately $1.11 billion in the US, according to IMS data as of January 2018.
Published by Globes [online], Israel business news - www.globes-online.com - on March 27, 2018
© Copyright of Globes Publisher Itonut (1983) Ltd. 2018